Kisspeptin-10

Also referred to as Kisspeptin, KP-10.

Status: Investigational. Kisspeptin-10 is not an FDA-approved drug product. It is studied as a research tool for probing the reproductive hormone axis, and no approved product built on it exists for any indication in the United States.

Kisspeptin-10 is a fragment of the kisspeptin peptide family studied for its role as an upstream trigger of the reproductive hormone cascade, sitting above GnRH, LH, and FSH release. It is not an FDA-approved drug product and no approved medicine is built on it. Researchers have used it mainly as an experimental probe to understand how the hypothalamus signals the pituitary and gonads, including in small human physiology studies. Patients typically ask about it in the context of reproductive hormone or libido-related questions, but the evidence base remains investigational and narrow.

What it is

Kisspeptin-10 is a short, ten-amino-acid fragment of the larger kisspeptin peptide, which is encoded by the KISS1 gene and acts on the KISS1R receptor. It sits at the top of the hypothalamic-pituitary-gonadal axis, upstream of gonadotropin-releasing hormone. As a peptide, it is unstable outside controlled laboratory or clinical-research conditions and is not formulated into any FDA-approved product.

Why people ask about it

Patients raise kisspeptin-10 after encountering research describing its central role in triggering puberty and regulating reproductive hormone pulses, and some extend that interest to questions about libido or hormonal balance. Because it sits so far upstream in the endocrine cascade, it draws attention from people looking for a single lever on reproductive hormone signalling. This interest runs well ahead of any approved clinical use.

Proposed mechanism

Laboratory and animal work proposes that kisspeptin binds KISS1R on GnRH neurons in the hypothalamus, triggering pulsatile GnRH release, which in turn drives pituitary LH and FSH secretion. This proposed mechanism places kisspeptin-10 as a gatekeeper of the reproductive axis rather than a direct actor on gonadal tissue. The strength of this evidence is greatest in animal models and in short human infusion studies, and it does not establish a therapeutic effect in general use.

What researchers have studied

Its role as an upstream trigger for GnRH pulsatility in animal and human physiology studies
Short intravenous infusion studies measuring LH and FSH responses in small cohorts
Investigational use in reproductive endocrinology research, including studies of puberty onset
Exploratory interest in its relationship to sexual arousal responses measured in laboratory settings
Comparison of kisspeptin signalling with other upstream regulators of the hypothalamic-pituitary-gonadal axis

Human evidence

Human data come mostly from short-duration intravenous infusion studies in research clinics, not from outpatient or long-term use.
Cohorts are typically small, often fewer than a few dozen participants, limiting how far conclusions can generalize.
Some studies have looked at brain and behavioural responses tied to arousal, but these are exploratory and not designed to establish a clinical benefit.
No large or long-term controlled trial supporting a specific indication has been identified.

Preclinical evidence

Animal studies identify kisspeptin signalling as necessary for the onset of puberty in several species.
Rodent models show that KISS1R activation triggers downstream GnRH neuron firing.
Cell-based receptor binding studies describe how kisspeptin-10 interacts with KISS1R relative to full-length kisspeptin.

What is not yet known

Whether repeated or long-term exposure has meaningful effects outside a controlled research infusion setting.
What an appropriate research protocol looks like outside supervised clinical studies.
How kisspeptin-10 compares to full-length kisspeptin or to other reproductive-axis compounds in practice.
Long-term safety across different ages, sexes, and health conditions.
Whether any observed laboratory effects would translate into a meaningful patient-relevant outcome.

Regulatory status and access

Any compounded preparation of kisspeptin-10 is not the same thing as an approved medicine and compounding is never a form of FDA approval. Ask about current availability. Only a physician can determine whether discussing this research area is appropriate after an evaluation.

Known and potential risks

As an unregulated research-market compound, product identity, purity, and sterility cannot be assumed and grey-market sourcing carries meaningful quality risk.
Effects on hormone-sensitive tissue are not fully characterized outside short supervised infusions.
Interactions with fertility treatments or hormone therapies have not been systematically studied.
There is no established safety monitoring framework for use outside a research protocol.
Any perceived hormonal effect could mask or delay diagnosis of an underlying endocrine condition.

Cautions and who may not be a candidate

Pregnancy or breastfeeding, given the peptide's direct role in reproductive hormone signalling.
Known or suspected hormone-sensitive conditions, including certain reproductive cancers.
Undiagnosed menstrual, fertility, or pubertal concerns, which warrant a diagnostic workup rather than a research peptide.
Use alongside fertility medications or hormone therapy without physician oversight.
Active endocrine disease affecting the hypothalamic-pituitary-gonadal axis.

Questions to discuss with a physician

What does the current research say about kisspeptin-10 and my specific health question?
Is there an FDA-approved option that addresses the same underlying concern?
What diagnostic testing would clarify whether my hormone axis is functioning as expected?
What are the known gaps in the human evidence for this peptide?
How would a grey-market product's lack of quality assurance factor into any risk discussion?
Are there interactions with medications or conditions I already have?

Frequently asked questions

Is kisspeptin-10 FDA-approved?

No. Kisspeptin-10 is not an FDA-approved drug product for any indication. It remains an investigational research compound studied mainly in short clinical physiology studies.

Does GOAL.MD sell kisspeptin-10?

This page is educational only. It does not describe an offer to sell, and it is not a substitute for an individualized medical evaluation.

What is kisspeptin-10 used for in research?

Researchers have used it mainly to study how the hypothalamus triggers GnRH release and downstream LH and FSH secretion, largely in short infusion studies.

Can kisspeptin-10 improve libido?

Some exploratory research has looked at arousal-related brain responses, but this evidence is preliminary and does not establish a reliable effect on libido in general use.

Is kisspeptin-10 the same as full-length kisspeptin?

No. Kisspeptin-10 is a shorter fragment of the larger kisspeptin peptide family, and research on one does not automatically apply to the other.

Is kisspeptin-10 safe?

Its safety profile outside short, supervised research infusions has not been established, and grey-market products carry additional quality risks that have not been studied.

Who studies kisspeptin-10?

It is studied mainly by reproductive endocrinology researchers investigating puberty, fertility, and hypothalamic-pituitary-gonadal signalling.

Can I get a prescription for kisspeptin-10?

There is no FDA-approved product to prescribe. A physician would need to evaluate whether any related, approved option is appropriate for your specific situation.

How is kisspeptin-10 typically studied?

Human studies have generally used controlled intravenous infusion protocols in clinical research settings rather than outpatient use.

Does kisspeptin-10 affect men and women differently?

Research has examined the reproductive axis in both sexes, but sex-specific responses are not fully characterized and require further study.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.